For research use only. Not for therapeutic Use.
Visnagin, an antioxidant furanocoumarin derivative, possess anti-inflammatory and analgesic properties. Visnagin has substantial potential to prevent Cerulein induced acute pancreatitis (AP). Visnagin possess promising vasodilator effects in vascular smooth muscles[1][2].
Visnagin (10 µM; for 4, 8, 16, 24 h) induces CYP1A1 transcription in HepG2 cells[1].
Visnagin (10 µM; for 16 h) elevates CYP1B1 gene expression in an aryl hydrocarbon receptor (AHR)-dependent manner, whereas MNF (3’-methoxy-4’-nitroflavone; 20 µM; pre-treated for 1 h) successfully counteracted this induction. Visnagin also enhances PAI-2 transcription in an AHR-dependent manner[1].
Visnagin (10, 30, 60 mg/kg; ip; for 7 days) is effective in reducing plasma amylase and lipase levels and reduces Cerulein (50 μg/kg, six, hourly i.p. injections) induced oxidative stress in male Swiss albino mice (age: 6-8 weeks, weighing 20-25 g)[1].
Visnagin dose dependently decreases the expression of IL-1β, IL-6, TNF-α and IL-17. It attenuates the levels of nuclear p65-NFκB. Visnagin improves the antioxidant defence by improving Nrf2 expression and halts pancreatic inflammation by suppressing NFκB and nitrotyrosine expression in the acinar cells[1].
| Catalog Number | R006812 |
| CAS Number | 82-57-5 |
| Synonyms | 4-methoxy-7-methylfuro[3,2-g]chromen-5-one |
| Molecular Formula | C13H10O4 |
| Purity | ≥95% |
| InChI | InChI=1S/C13H10O4/c1-7-5-9(14)12-11(17-7)6-10-8(3-4-16-10)13(12)15-2/h3-6H,1-2H3 |
| InChIKey | NZVQLVGOZRELTG-UHFFFAOYSA-N |
| SMILES | CC1=CC(=O)C2=C(O1)C=C3C(=C2OC)C=CO3 |
| Reference | [1]. Radim Vrzal, et al. Khellin and visnagin differentially modulate AHR signaling and downstream CYP1A activity in human liver cells. PLoS One. 2013 Sep 19;8(9):e74917. [2]. Lakshmi Priya Pasari, et al. Visnagin attenuates acute pancreatitis via Nrf2/NFκB pathway and abrogates associated multiple organ dysfunction. Biomed Pharmacother. 2019 Apr;112:108629. |
